SEATTLE, Nov. 20 /PRNewswire/ -- IDRI (Infectious Disease Research Institute) and Immune Design Corp. announced today that they have entered into an agreement pursuant to which Immune Design Corp. is granted a worldwide exclusive license for the research, development, and commercialization of IDRI's Glycopyranosyl Lipid Adjuvant (GLA) technology for products targeting a number of indications. Focusing on its mission to fight infectious diseases of the developing world, IDRI retains worldwide exclusive rights to GLA for selected diseases affecting predominately the developing world. Under the agreement, IDRI will receive an upfront payment, milestones, and royalty payments as well as shares in Immune Design Corp. Further details on the financial terms were not disclosed.
GLA is specifically engineered to improve a vaccine's interaction with the immune system resulting in an enhanced and directed immune response to the vaccine. "We are excited by the promising preclinical results observed so far with GLA," said Chris Clegg, VP Operations and Technology at Immune Design Corp., a Seattle biotech startup focused on novel immunization strategies. "This innovative adjuvant could drive a major shift in the vaccine field."
"We are using GLA in several of IDRI's priority programs but we also think that it has great potential against diseases outside our scope of action," said Curt Malloy, Senior Vice President, Operations and General Counsel, IDRI. "While we retain the necessary rights to pursue our mission against diseases of poverty, revenues generated by this agreement will assist our research and development activities."
As part of its commitment to provide the not-for-profit sector access to its adjuvant technology, IDRI also retains rights to conduct non-commercial research with GLA and will still have the right to provide it to not-for- profit organizations.
Importantly, Immune Design Cor
|SOURCE IDRI (Infectious Disease Research Institute) and Immune Design Corp.|
Copyright©2008 PR Newswire.
All rights reserved